Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Oct;60(10):4009–4014. doi: 10.1128/iai.60.10.4009-4014.1992

Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.

L C Paoletti 1, M R Wessels 1, F Michon 1, J DiFabio 1, H J Jennings 1, D L Kasper 1
PMCID: PMC257430  PMID: 1398913

Abstract

Group B streptococci (GBS) are the most common cause of bacterial sepsis and meningitis in neonates in the United States. Although the capsular polysaccharide of GBS is an important virulence factor, it is variably immunogenic in humans. In this report, we have increased the immunogenicity of GBS type II polysaccharide by coupling it to tetanus toxoid (TT). Like other GBS capsular polysaccharides, the type II polysaccharide has side chains terminating in sialic acid. Controlled periodate oxidation of native II polysaccharide resulted in the conversion of 7% of sialic acid residues to an analog of sialic acid, 5-acetamido-3,5-dideoxy-D-galactosyloctulosonic acid. TT was conjugated to free aldehyde groups created on the oxidized sialic acid residues by reductive amination. Serum from rabbits vaccinated with type II-TT conjugate (II-TT) vaccine contained antibodies specific to type II polysaccharide as well as to TT, whereas rabbits vaccinated with uncoupled native type II polysaccharide failed to produce a type-specific antibody response. Antibodies elicited by II-TT vaccine were serotype specific and mediated phagocytosis and killing in vitro of type II GBS by human peripheral blood leukocytes. Serum from rabbits vaccinated with II-TT vaccine provided 100% protection in a mouse model of GBS type II infection. Antibodies induced by II-TT vaccine were specific for the native but not desialylated type II polysaccharide, suggesting that an important antigenic epitope of II-TT vaccine was dependent on the presence of sialic acid. Therefore, the coupling strategy which selectively modified a portion of the sialic acid residues of types II polysaccharide before coupling the polysaccharide to TT preserved the epitope essential to protective immunity and enhanced the immunogenicity of the polysaccharide.

Full text

PDF
4009

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avery O. T., Goebel W. F. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : V. THE IMMUNOLOGICAL SPECIFITY OF AN ANTIGEN PREPARED BY COMBINING THE CAPSULAR POLYSACCHARIDE OF TYPE III PNEUMOCOCCUS WITH FOREIGN PROTEIN. J Exp Med. 1931 Jul 31;54(3):437–447. doi: 10.1084/jem.54.3.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J., Edwards M. S., Kasper D. L. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981 Oct;68(4):544–549. [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L. Group B streptococcal vaccines. Rev Infect Dis. 1985 Jul-Aug;7(4):458–467. doi: 10.1093/clinids/7.4.458. [DOI] [PubMed] [Google Scholar]
  5. Baker C. J., Rench M. A., Edwards M. S., Carpenter R. J., Hays B. M., Kasper D. L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988 Nov 3;319(18):1180–1185. doi: 10.1056/NEJM198811033191802. [DOI] [PubMed] [Google Scholar]
  6. Baltimore R. S., Kasper D. L., Baker C. J., Goroff D. K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed] [Google Scholar]
  7. De Cueninck B. J., Greber T. F., Eisenstein T. K., Swenson R. M., Shockman G. D. Isolation, chemical composition, and molecular size of extracellular type II and type Ia polysaccharides of group B streptococci. Infect Immun. 1983 Aug;41(2):527–534. doi: 10.1128/iai.41.2.527-534.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dillon H. C., Jr, Khare S., Gray B. M. Group B streptococcal carriage and disease: a 6-year prospective study. J Pediatr. 1987 Jan;110(1):31–36. doi: 10.1016/s0022-3476(87)80283-4. [DOI] [PubMed] [Google Scholar]
  9. Freimer E. H. Type-specific polysaccharide antigens of group B streptococci. II. The chemical basis for serological specificity of the type II HCl antigen. J Exp Med. 1967 Mar 1;125(3):381–392. doi: 10.1084/jem.125.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. GELFAND H. M., FOX J. P., LEBLANC D. R., ELVEBACK L. Studies on the development of natural immunity to poliomyelitis in Louisiana. V. Passive transfer of polioantibody from mother to fetus, and natural decline and disappearance of antibody in the infant. J Immunol. 1960 Jul;85:46–55. [PubMed] [Google Scholar]
  11. Goebel W. F., Avery O. T. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : IV. THE SYNTHESIS OF THEp-AMINOBENZYL ETHER OF THE SOLUBLE SPECIFIC SUBSTANCE OF TYPE III PNEUMOCOCCUS AND ITS COUPLING WITH PROTEIN. J Exp Med. 1931 Jul 31;54(3):431–436. doi: 10.1084/jem.54.3.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gray B. M. ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes. J Immunol Methods. 1979;28(1-2):187–192. doi: 10.1016/0022-1759(79)90340-5. [DOI] [PubMed] [Google Scholar]
  13. Hobbs J. R., Davis J. A. Serum gamma-G-globulin levels and gestational age in premature babies. Lancet. 1967 Apr 8;1(7493):757–759. doi: 10.1016/s0140-6736(67)91369-4. [DOI] [PubMed] [Google Scholar]
  14. Insel R. A., Anderson P. W. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J Exp Med. 1986 Feb 1;163(2):262–269. doi: 10.1084/jem.163.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jennings H. J., Lugowski C., Ashton F. E. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect Immun. 1984 Jan;43(1):407–412. doi: 10.1128/iai.43.1.407-412.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jennings H. J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981 Sep;127(3):1011–1018. [PubMed] [Google Scholar]
  17. Jennings H. J., Rosell K. G., Katzenellenbogen E., Kasper D. L. Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus. J Biol Chem. 1983 Feb 10;258(3):1793–1798. [PubMed] [Google Scholar]
  18. Kasper D. L., Baker C. J., Galdes B., Katzenellenbogen E., Jennings H. J. Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J Clin Invest. 1983 Jul;72(1):260–269. doi: 10.1172/JCI110965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  20. Lagergard T., Shiloach J., Robbins J. B., Schneerson R. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun. 1990 Mar;58(3):687–694. doi: 10.1128/iai.58.3.687-694.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975 Jul 1;142(1):165–179. doi: 10.1084/jem.142.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Michon F., Katzenellenbogen E., Kasper D. L., Jennings H. J. Structure of the complex group-specific polysaccharide of group B Streptococcus. Biochemistry. 1987 Jan 27;26(2):476–486. doi: 10.1021/bi00376a020. [DOI] [PubMed] [Google Scholar]
  23. Paoletti L. C., Kasper D. L., Michon F., DiFabio J., Holme K., Jennings H. J., Wessels M. R. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem. 1990 Oct 25;265(30):18278–18283. [PubMed] [Google Scholar]
  24. Paoletti L. C., Kasper D. L., Michon F., DiFabio J., Jennings H. J., Tosteson T. D., Wessels M. R. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992 Jan;89(1):203–209. doi: 10.1172/JCI115564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Svenson S. B., Lindberg A. A. Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers. J Immunol Methods. 1979;25(4):323–335. doi: 10.1016/0022-1759(79)90025-5. [DOI] [PubMed] [Google Scholar]
  27. WARREN L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959 Aug;234(8):1971–1975. [PubMed] [Google Scholar]
  28. Walsh J. A., Hutchins S. Group B streptococcal disease: its importance in the developing world and prospect for prevention with vaccines. Pediatr Infect Dis J. 1989 May;8(5):271–277. [PubMed] [Google Scholar]
  29. Wessels M. R., Paoletti L. C., Kasper D. L., DiFabio J. L., Michon F., Holme K., Jennings H. J. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990 Nov;86(5):1428–1433. doi: 10.1172/JCI114858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zigterman J. W., van Dam J. E., Snippe H., Rotteveel F. T., Jansze M., Willers J. M., Kamerling J. P., Vliegenthart J. F. Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect Immun. 1985 Feb;47(2):421–428. doi: 10.1128/iai.47.2.421-428.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES